Background
Cristina Adriana Popa
ACEing the management of advanced CKD

This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond

ACEing the management of advanced CKD
Background
swapnil hiremath
BPROAD: Sprinting down the BP Road in Diabetes

This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.

BPROAD: Sprinting down the BP Road in Diabetes
news, Meta
joel topf
#HCWvsHunger 2024

Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.

#HCWvsHunger 2024
Background
Brian Rifkin
Potassium Rollercoaster Heartbreak

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

Potassium Rollercoaster Heartbreak
Background
Jade Teakell
FLOZINATing to the Future- Long Term Effects of ...

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD

nature medicine

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

Creatinine to Cystatin C: Time to Change?

Creatinine to Cystatin C: Time to Change?

This week, we will discuss a paper from Nature Medicine. Cystatin C has been around for a while, but not taken off in routine practice. Is it time for it to do so? In this study, authors from Glasgow using the UKBiobank data show that cystatin C improves the prediction of bad outcomes.